Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Total Liabilities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Total Liabilities data on record, last reported at $352.3 million in Q1 2026.

  • On a quarterly basis, Total Liabilities rose 97.83% to $352.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $352.3 million, a 97.83% increase, with the full-year FY2025 number at $317.2 million, up 54.36% from a year prior.
  • Total Liabilities reached $352.3 million in Q1 2026 per PCVX's latest filing, up from $317.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for PCVX hit a ceiling of $352.3 million in Q1 2026 and a floor of $43.2 million in Q1 2022.
  • A 5-year average of $147.3 million and a median of $107.3 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: dropped 22.09% in 2022, then skyrocketed 218.56% in 2023.
  • Tracing PCVX's Total Liabilities over 5 years: stood at $52.6 million in 2022, then surged by 218.56% to $167.4 million in 2023, then rose by 22.72% to $205.5 million in 2024, then soared by 54.36% to $317.2 million in 2025, then rose by 11.06% to $352.3 million in 2026.
  • Business Quant data shows Total Liabilities for PCVX at $352.3 million in Q1 2026, $317.2 million in Q4 2025, and $278.7 million in Q3 2025.